Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3R1 | P27986 | 17/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 17/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9947956 | 0.87 | ABCB1 (0.37) | PIK3R1PIK3CAGPR119 | |
| SCHEMBL10217084 | 0.83 | HTR2C (0.42) | PIK3R1PIK3CAGPR119 | |
| SCHEMBL9948007 | 0.81 | HTR2A (0.39) | PIK3R1PIK3CA | |
| SCHEMBL10217078 | 0.79 | SMARCA2 (0.38) | PIK3R1PIK3CAGPR119 | |
| SCHEMBL9948082 | 0.78 | POLB (0.37) | PIK3R1PIK3CAGPR119 | |
| SCHEMBL9947948 | 0.77 | HTR2C (0.41) | PIK3R1PIK3CA | |
| SCHEMBL9948239 | 0.76 | HTR2C (0.42) | — | |
| SCHEMBL10217761 | 0.74 | HTR2C (0.56) | PIK3R1PIK3CA | |
| SCHEMBL2571551 | 0.74 | HTR2C (0.47) | GPR119 | |
| SCHEMBL9948430 | 0.72 | HTR2C (0.41) | GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9346816-B2 | 6,7,8,9-tetrahydro-5H-1,4,7,10a-tetraaza-cyclohept[f]indene derivatives, pharmaceutical compositions containing these compounds, their use and processes for preparing them | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-05-24 | — | — | US | disclosed |
| US-20140066428-A1 | 6,7,8,9-Tetrahydro-5H-1,4,7,10a-tetraaza-cyclohept[f]indene derivatives, pharmaceutical compositions containing these compounds, their use and processes for preparing them | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-03-06 | — | — | US | disclosed |
| EP-2384328-B1 | 6,7,8,9-TETRAHYDRO-5H-1,4,7,10A-TETRAAZA-CYCLOHEPT[F]INDENE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS, THEIR USE AND PROCESS FOR PREPARING THEM | BOEHRINGER INGELHEIM INT (DE) | 2013-02-13 | — | — | EP | disclosed |
| US-20120165304-A1 | 6,7,8,9-Tetrahydro-5H-1,4,7,10a-tetraaza-cyclohept[f]indene derivatives, pharmaceutical compositions containing these compounds, their use and processes for preparing them | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165304-A1 | 6,7,8,9-Tetrahydro-5H-1,4,7,10a-tetraaza-cyclohept[f]indene derivatives, pharmaceutical compositions containing these compounds, their use and processes for preparing them | HTR1A, HTR2C, TPH1 | PIK3R1 1428/4885PIK3CA 1579/4885PIK3CD 1670/4885 |
| US-20140066428-A1 | 6,7,8,9-Tetrahydro-5H-1,4,7,10a-tetraaza-cyclohept[f]indene derivatives, pharmaceutical compositions containing these compounds, their use and processes for preparing them | HTR1A, HTR2C, TPH1 | PIK3R1 1365/4885PIK3CA 1544/4885PIK3CD 1707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.